BioArctic AB (publ) (BRCTF)
OTCMKTS
· Delayed Price · Currency is USD
19.65
0.00 (0.00%)
Dec 24, 2024, 4:00 PM EST
BioArctic AB Revenue
BioArctic AB had revenue of 76.63M SEK in the quarter ending September 30, 2024, a decrease of -63.31%. This brings the company's revenue in the last twelve months to 167.14M, down -72.46% year-over-year. In the year 2023, BioArctic AB had annual revenue of 616.00M with 168.49% growth.
Revenue (ttm)
167.14M SEK
Revenue Growth
-72.46%
P/S Ratio
n/a
Revenue / Employee
1.90M SEK
Employees
88
Market Cap
1.61B USD
Revenue Chart
* This company reports financials in SEK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 616.00M | 386.56M | 168.49% |
Dec 31, 2022 | 229.43M | 203.77M | 794.02% |
Dec 31, 2021 | 25.66M | -39.54M | -60.64% |
Dec 31, 2020 | 65.21M | -217.74M | -76.95% |
Dec 31, 2019 | 282.94M | -439.28M | -60.82% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 1, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sandoz Group AG | 10.11B |
Telix Pharmaceuticals Limited | 430.80M |
Elekta AB (publ) | 1.66B |
Ryman Healthcare Limited | 458.44M |
Verano Holdings Corp. | 897.57M |
Vireo Growth Inc. | 98.53M |
Medexus Pharmaceuticals Inc. | 104.76M |
BioArctic AB News
- 21 days ago - Leqembi® approved in Mexico - PRNewsWire
- 4 weeks ago - Leqembi® launched in South Korea - PRNewsWire
- 5 weeks ago - CHMP issues positive recommendation for approval of lecanemab in the EU - PRNewsWire
- 6 weeks ago - Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion - PRNewsWire
- 7 weeks ago - Invitation to presentation of BioArctic's third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET - PRNewsWire
- 2 months ago - Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile - PRNewsWire
- 2 months ago - Leqembi® revenue totaled JPY 10 billion in the third quarter 2024 - Benzinga
- 2 months ago - Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease - PRNewsWire